News from EAS 2025: 10-year data of the LOWER registry

Dirk Blom at EAS

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
EAS 2025
Durable reductions in LDL-c with ANGPTL3 siRNA in patients with HoFH
- Prof. Frederick Raal
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
EAS 2025
Higher Lp(a) levels associated with recurrent ASCVD events, regardless of sex and race
- Børge G. Nordestgaard, MD, DMSc
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
EAS 2025
Obicetrapib lowers LDL-c and other atherogenic lipids in patients at high risk of CV events
- Stephen Nicholls, FRACP, FACC, FESC, FAHA